These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20393344)

  • 21. Metabolic modulation in heart failure: high time for a definitive clinical trial.
    Ashrafian H; Neubauer S
    Heart; 2011 Feb; 97(4):267-8. PubMed ID: 21258118
    [No Abstract]   [Full Text] [Related]  

  • 22. The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo.
    Schwarzer M; Faerber G; Rueckauer T; Blum D; Pytel G; Mohr FW; Doenst T
    Basic Res Cardiol; 2009 Sep; 104(5):547-57. PubMed ID: 19294446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modification of myocardial substrate use as a therapy for heart failure.
    Abozguia K; Clarke K; Lee L; Frenneaux M
    Nat Clin Pract Cardiovasc Med; 2006 Sep; 3(9):490-8. PubMed ID: 16932766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor Etomoxir.
    Schmitz FJ; Rösen P; Reinauer H
    Horm Metab Res; 1995 Dec; 27(12):515-22. PubMed ID: 8750778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of metabolic approach in diabetic patients with coronary artery disease.
    Fragasso G; Salerno A; Spoladore R; Cera M; Montanaro C; Margonato A
    Curr Pharm Des; 2009; 15(8):857-62. PubMed ID: 19275650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure.
    Lopaschuk GD
    Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):228-30. PubMed ID: 16959756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic therapy for heart failure.
    Essop MF; Opie LH
    Eur Heart J; 2004 Oct; 25(20):1765-8. PubMed ID: 15474689
    [No Abstract]   [Full Text] [Related]  

  • 28. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates.
    Luiken JJ; Niessen HE; Coort SL; Hoebers N; Coumans WA; Schwenk RW; Bonen A; Glatz JF
    Biochem J; 2009 Apr; 419(2):447-55. PubMed ID: 19138173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.
    Dalal JJ; Mishra S
    Indian Heart J; 2017; 69(3):393-401. PubMed ID: 28648439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic modulation as a target for heart failure treatment: current perspective.
    Chenniapan S; Manchanda SC
    Indian Heart J; 2007; 59(4):370-4. PubMed ID: 19126947
    [No Abstract]   [Full Text] [Related]  

  • 31. Metabolic modulators for chronic cardiac ischemia.
    Parang P; Singh B; Arora R
    J Cardiovasc Pharmacol Ther; 2005 Dec; 10(4):217-23. PubMed ID: 16382258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medicines interacting with mitochondria: anti-ischemic effects of trimetazidine].
    Spedding M; Tillement JP; Morin D; Le Ridant A
    Therapie; 1999; 54(5):627-35. PubMed ID: 10667101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential application of late sodium current blockade in the treatment of heart failure and atrial fibrillation.
    Doshi D; Morrow JP
    Rev Cardiovasc Med; 2009; 10 Suppl 1():S46-52. PubMed ID: 19898288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.
    Gao D; Ning N; Niu X; Hao G; Meng Z
    Heart; 2011 Feb; 97(4):278-86. PubMed ID: 21134903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel drugs for treating angina.
    Jones DA; Timmis A; Wragg A
    BMJ; 2013 Sep; 347():f4726. PubMed ID: 24018101
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
    Fragasso G; Perseghin G; De Cobelli F; Esposito A; Palloshi A; Lattuada G; Scifo P; Calori G; Del Maschio A; Margonato A
    Eur Heart J; 2006 Apr; 27(8):942-8. PubMed ID: 16510466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?
    Ibrahim OA; Dunlap ME
    Curr Heart Fail Rep; 2005 Aug; 2(2):89-93. PubMed ID: 16036056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perhexiline.
    Ashrafian H; Horowitz JD; Frenneaux MP
    Cardiovasc Drug Rev; 2007; 25(1):76-97. PubMed ID: 17445089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Drug therapy of cardiac insufficiency: status 1995].
    Rickenbacher P; Buser P; Osswald S; Pfisterer M
    Schweiz Med Wochenschr; 1996 May; 126(21):933-45. PubMed ID: 8693314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study.
    Holubarsch CJ; Rohrbach M; Karrasch M; Boehm E; Polonski L; Ponikowski P; Rhein S
    Clin Sci (Lond); 2007 Aug; 113(4):205-12. PubMed ID: 17319797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.